The content is available as a PDF (223.2 KB).
Bibliográfia
- 1.Witztum L.W. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman J.G., Limbird L.E., Morinoff P.B., Ruddon R.W., Goodman A., editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 9.a. McGraw-Hill; Nueva York: 1996. pp. 875–897. [Google Scholar]
- 2.Ozdemir O., Boran M., Gokce V., Uzun Y., Kocak B., Korkmaz S. A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy – a case report. Angiology. 2000;51:695–697. [PubMed] [Google Scholar]
- 3.Bermingham R.P., Whitsitt T.B., Smart M.L., Nowak D.P., Scalley R.D. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. Am J Health Syst Pharm. 2000;57:461–464. doi: 10.1093/ajhp/57.5.461. [DOI] [PubMed] [Google Scholar]
- 4.Alexandridis G., Pappas G.A., Elisaf M.S. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med. 2000;109:261–262. doi: 10.1016/s0002-9343(00)00514-3. [DOI] [PubMed] [Google Scholar]
- 5.Guyton J.R., Dujovne C.A., Illingworth D.R. Dual hepatic metabolism of cerivastatin-clarification. Am J Cardiol. 1999;84:497. [PubMed] [Google Scholar]
- 6.Mathew T., Chow R., Isaacs D., Lander C., MacNeil J., Shenfield G. Cerivastatin and rhabdomyolysis – avoid gemfibrozil. Aust Adverse Drug React Bull. 2001;20:3. [Google Scholar]
- 7.Ficha técnica de Lipobay® (Laboratorio Bayer)
- 8.Ficha técnica de Trialmin® (Laboratorio Menarini)
- 9.Ministerio de Sanidad y Consumo. Agencia Española del Medicamento. Subdirección General de Seguridad de Medicamentos.Comunicación sobre cerivastatina y casos de rabdomiolisis.(Ref.2001/03,30 de mayo de 2001) (URL: http://www.msc.es/agemed/Princip.htm)